Dasatinib overrides the differentiation blockage in a patient with mutant-KIT D816V positive CBFβ-MYH11 leukemia

Activating KIT D816V mutations are frequently found in CBF AML, which predicts for an unfavorable outcome. Dasatinib is a potent inhibitor of wildtype and mutant-KIT isoforms – including D816V. We now provide proof of antileukemic efficacy in a patient with relapsing mutant-KIT D816V CBF AML. Import...

Descripción completa

Detalles Bibliográficos
Autores principales: Kampa-Schittenhelm, Kerstin M., Vogel, Wichard, Bonzheim, Irina, Fend, Falko, Horger, Marius, Kanz, Lothar, Soekler, Martin, Schittenhelm, Marcus M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5837740/
https://www.ncbi.nlm.nih.gov/pubmed/29545943
http://dx.doi.org/10.18632/oncotarget.24376

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5837740/
https://www.ncbi.nlm.nih.gov/pubmed/29545943
http://dx.doi.org/10.18632/oncotarget.24376

Ejemplares similares